Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Tan

Showing results (1071-1080 of 1,101) with videos related to

Pageof 111
Sort By:
Nature|May 18, 2018
Bystander CD8<sup>+</sup> T cells are abundant and phenotypically distinct in human tumour infiltratesYannick Simoni, Etienne Becht, Michael Fehlings, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint BlockadeKevin L M Chua, Michael Fehlings, Eugenia L L Yeo, et al.
The British Journal of Dermatology|October 2, 2020
Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo TrialK S Thomas, J M Batchelor, P Akram, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Immunity|December 18, 2016
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and FrequencyYannick Simoni, Michael Fehlings, Henrik N Kløverpris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisoneL Wang, S M Dehm, D W Hillman, et al.
The Journal of Prevention of Alzheimer'S Disease|May 6, 2024
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and ProgressS-Y Li, X-Y Xie, D Liu, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Pageof 111

Showing results (1071-1080 of 1,101) with videos related to

Sort By:
Pageof 111
Nature|May 18, 2018
Bystander CD8<sup>+</sup> T cells are abundant and phenotypically distinct in human tumour infiltratesYannick Simoni, Etienne Becht, Michael Fehlings, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint BlockadeKevin L M Chua, Michael Fehlings, Eugenia L L Yeo, et al.
The British Journal of Dermatology|October 2, 2020
Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo TrialK S Thomas, J M Batchelor, P Akram, et al.
JCO Precision Oncology|July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center ExperienceAmanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Immunity|December 18, 2016
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and FrequencyYannick Simoni, Michael Fehlings, Henrik N Kløverpris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisoneL Wang, S M Dehm, D W Hillman, et al.
The Journal of Prevention of Alzheimer'S Disease|May 6, 2024
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and ProgressS-Y Li, X-Y Xie, D Liu, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Pageof 111